Cetuximab in non-melanoma skin cancer

Bibliography

• Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011;164:291-307
   PubMed Web of Science ®Google Scholar
• Stang A, Ziegler S, Buchner U, Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach. Int J Dermatol 2007;46:564-70
   PubMed Web of Science ®Google Scholar
• Brewster DH, Bhatti LH, Inglis JH, Recent trends in incidence of nonmelanoma skin cancer in the East of Scotland, 1992-2003. Br J Dermatol 2007;156:1295-300
   PubMed Web of Science ®Google Scholar
• Revenga Arranz F, Paricio Rubio JF, Mar Vasquez Salvado M, del Villar Sordo V. Descriptive epidemiology of basal cell carcinoma and cutaneous squamous cell carcinoma in Soria (north-east Spain) 1998-2000: a hospital-based survey. J Eur Acad Dermatol Venereol 2004;18:137-41
   PubMed Web of Science ®Google Scholar
• Ho T, Byrne PJ. Evaluation and initial management of the patient with facial skin cancer. Facial Plast Surg Clin North Am 2009;17:301-7
   PubMedGoogle Scholar
• Jambusaria-Pahlajani A, Miller CJ, Quon H, Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009;35:574-85
   PubMed Web of Science ®Google Scholar
• Pingnon JP, Bourhis J, Domenge C, Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-55
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 2010;15:1320-8
   PubMed Web of Science ®Google Scholar
• Amini S, Viera MH, Valins W, Berman B. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthetic Surg 2010;3:20-34
   PubMedGoogle Scholar
• Wollina U, Hansel G, Koch A, Kostler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005;131:300-4
   PubMed Web of Science ®Google Scholar
• Jirakulaporn T, Endrizzi B, Lindgren B, Capecitabine for skin cancer prevention in solid organ-transplanted recipients. Clin Transplant 2011;25(4):541-8
   PubMed Web of Science ®Google Scholar
• Wollina U. Histochemistry of the human hair follicle. EXS 1997;78:31-58
   PubMedGoogle Scholar
• Wollina U, Frenkl A, Knoll B, Inhibition of signal transduction in EGF-dependent epithelial cell lines. Int J Mol Med 2003;12:673-7
   PubMed Web of Science ®Google Scholar
• Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract 2011;207:337-42
   PubMed Web of Science ®Google Scholar
• Brand TM. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 2011;12:419-32
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-18
   PubMed Web of Science ®Google Scholar
• Humbert Y. Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004;5:1621-33
   PubMed Web of Science ®Google Scholar
• Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107-27
   PubMed Web of Science ®Google Scholar
• Cunninham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
   PubMed Web of Science ®Google Scholar
• Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010;32:1412-21
   Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors – impact on future treatment strategies. Nat Rev Clin Oncol 2010;9:493-507
   Web of Science ®Google Scholar
• Niyazi M, Maihoefer C, Krause M, Radiotherapy and “new” drugs – new side effects? Radiat Oncol 2011;6:177
   PubMed Web of Science ®Google Scholar
• Robert F, Ezekiel MP, Spencer SA. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM Giral J, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase III randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
   PubMed Web of Science ®Google Scholar
• Jensen AD, Bergmann ZP, Garcia-Huttenlocher H, Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multimorbid patient: a single-centre experience. Head Neck Oncol 2010;2:34
   PubMedGoogle Scholar
• Dequanter D, Shala M, Paulus P, Lothaire P. Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials. Cancer Manag Res 2010;2:165-8
   PubMedGoogle Scholar
• Walsh L, Gillham C, Dunne M, Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 2011;98:38-41
   PubMed Web of Science ®Google Scholar
• Comet B, Kramar A, Faivre-Rierret M, Salvage stereotactic reiradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2012; In press
   PubMed Web of Science ®Google Scholar
• Fogarty GB, Conus NM, Chu J, McArthur G. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 2007;156:92-8
   PubMed Web of Science ®Google Scholar
• Schlauder SM, Calder KB, Moody P, Morgan MB. HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma. Am J Dermatopathol 2007;29:559-63
   PubMed Web of Science ®Google Scholar
• Maubec E, Duvillard P, Velasco V, Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005;25:1205-10
   PubMed Web of Science ®Google Scholar
• Maubec E, Petrow P, Scheer-Senyarich I, Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29:3419-26
   PubMed Web of Science ®Google Scholar
• Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007;143:889-92
   PubMed Web of Science ®Google Scholar
• Suen JK, Bressler L, Shord SS, Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007;18:827-9
   PubMed Web of Science ®Google Scholar
• Laili A, Pinc A, Pieczkowski F, Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2008;6:1066-9
   PubMed Web of Science ®Google Scholar
• Arnold AW, Bruckner-Tuderman I, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009;219:80-3
   PubMed Web of Science ®Google Scholar
• Rubio Casadevall J, Grana-Suarez B, Hernandez-Ygue X, Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab. Eur J Dermatol 2009;19:163-5
   PubMed Web of Science ®Google Scholar
• Miller K, Sherman W, Ratner D. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg 2010;36:2069-74
   PubMed Web of Science ®Google Scholar
• Kanakamedala MR, Packianathan S, Vijayakumar S. Lack of cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature. Radiat Oncol 2010;5:38
   PubMed Web of Science ®Google Scholar
• Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck 2011;33:286-8
   PubMed Web of Science ®Google Scholar
• Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep 2011;3:e57
   Google Scholar
• Giacchero D, Barriere J, Benezery K, Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma – a report of eight cases. Clin Oncol (R Coll Radiol) 2011;23:716-18
   PubMed Web of Science ®Google Scholar
• Caron J, Dereure O, Kerob D, Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol 2009;161:702-3
   PubMed Web of Science ®Google Scholar
• Gessner K, Wichmann G, Boehm A, Therapeutic options for treatment of merkel cell carcinoma. Eur Arch Otorhinolaryngol 2011;268:443-8
   PubMed Web of Science ®Google Scholar
• Ishiguro M, Watanabe T, Yamaguchi K, A Japanese post-marketing surveillance of cetucimab (Erbitux®) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012;42(4):287-94
   PubMed Web of Science ®Google Scholar
• Song X, Long SR, Barber B, Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 2012;7:56-65
   PubMedGoogle Scholar
• Mittmann N, Seung SJ. Rash rates with EGFR inhibitors: meta-analysis. Curr Oncol 2011;18:e54-63
   PubMed Web of Science ®Google Scholar
• Foley KA, Wang PF, Barber BL, Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol 2010;21:1455-61
   PubMed Web of Science ®Google Scholar
• Hoag JB, Azizi A, Doherty TJ, Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 2009;28:113
   PubMed Web of Science ®Google Scholar
• De Vos FY, Driessen CM, Jaspers HC, Cetuximab-induced pneumonitis in head and neck cancer patients. Oral Oncol 2012; In press
   PubMed Web of Science ®Google Scholar
• Leard LE, Cho BK, Jones KD, Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007;26:1340-4
   PubMed Web of Science ®Google Scholar
• Criado PR, Lima AA. Blepharitis and trichomegaly induced by cetuximab. An Bras Dermatol 2010;85:919-20
   PubMed Web of Science ®Google Scholar
• Ramirez-Soria MP, Espana-Gregori E, Avino-Martinez J, Pastor-Pascual F. Blepharitis related to cetuximab treatment in an advanced colorectal cancer patient. Arch Soc Esp Oftalmol 2008;83:665-8
   PubMedGoogle Scholar
• Turan H, Kaya E, Gurlevik Z, Neutrophilic eccrine hidradenitis induced by cetuximab. Cutan Ocul Toxicol 2011; In press
   PubMed Web of Science ®Google Scholar
• Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Dermatol 2007;357:514-15
   PubMed Web of Science ®Google Scholar
• Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 2011;17:4400-13
   PubMed Web of Science ®Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33
   PubMed Web of Science ®Google Scholar
• Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with matastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010;24:453-9
   PubMed Web of Science ®Google Scholar
• Santiago F, Goncalo M, Resi JP, Figueiredo A. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients. An Bars Dermatol 2011;86:483-90
   PubMed Web of Science ®Google Scholar
• Pinto C, Barone CA, Girolomoni G, Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011;16:228-38
   PubMed Web of Science ®Google Scholar
• Taguchi K, Fukunaga A, Okuno T, Nishigori C. Successful treatment with adapalene of cetuximab-induced acneiform eruptions. J Dermatol 2011; doi:10.111/j.1346-8138.2011.01424.x.
   Google Scholar
• Eiling E, Brandt M, Schwarz T, Hauschild A. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption. Arch Dermatol 2008;144:1236-8
   PubMed Web of Science ®Google Scholar
• Jatoi A, Rowland K, Sloan JA, Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-53
   PubMed Web of Science ®Google Scholar
• Gobbo M, Ottavani G, Mustacchi G, Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach. Lasers Med Sci 2011; In press
   PubMed Web of Science ®Google Scholar
• Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010;15:1002-8
   PubMed Web of Science ®Google Scholar
• Orditura M, De Vita F, Galizia G, Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009;21:1023-8
   PubMed Web of Science ®Google Scholar
• Klinghammer K, Knodler M, Schmittel A, Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2010;16:304-10
   PubMed Web of Science ®Google Scholar
• Jatoi A, Thrower A, Sloan JA, Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010;15:1016-22
   PubMed Web of Science ®Google Scholar
• Wollina U. Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol 2001;15:82-4
   PubMed Web of Science ®Google Scholar
• Caro I, Low JA. The role of the hedgehog signalling pathway in the development of basal cell carcinoma and opportunities for treatment. J Clin Cancer 2010;16:3335-9
   PubMed Web of Science ®Google Scholar
• Galer CE, Corey CL, Wang Z, Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I reduces angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011;33:189-98
   PubMed Web of Science ®Google Scholar
• Tomkova H, Kohoutek M, Zabojnikova M, Cetuximab-induced cutaneous toxicity. J Eur Acad Dermatol Venereol 2010;24:692-6
   PubMed Web of Science ®Google Scholar
• Garibaldi DC, Adler RA. Cicatrical ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 2007;23:62-3
   PubMed Web of Science ®Google Scholar
• Tsuboi K, Kawase Y, Okochi O, Cetuximab-associated skin ulceration in patients with metastatic colorectal cancer: a case report. Gan To Kagaku Ryoho 2011;38:1549-52
   PubMedGoogle Scholar
• Eames T, Kroth J, Flaig MJ, Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 2009;90:202-3
   Web of Science ®Google Scholar
• Tscharner GG, Buhler S, Borner M, Hunziker T. Grover's disease induced by cetuximab. Dermatology 2006;213:37-9
   PubMed Web of Science ®Google Scholar